Lumida
/PROK
⌘K
ProKidney Corp

ProKidney Corp

PROK
$1.80USD↓-2.17%-0.04 today

MARKET CAP

544.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

  • ↑Complete enrollment of 320 patients in Phase 3 PROACT trial; topline data due Q2 2027
  • ↑$181.6 million cash reserves fund operations through mid-2027, enabling pipeline advancement
  • ↓Q2 2026 revenue $0.15 million, missing estimates by 31.8%, highlighting weak commercial dynamics
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

ProKidney Corp. (NASDAQ: PROK) is an emerging biotechnology company focused on developing advanced cell therapies, specifically its lead product, rilparencel, aimed at treating advanced chronic kidney disease associated with type 2 diabetes. Positioned within the healthcare and biotechnology sectors, ProKidney operates at a critical juncture, where it seeks to address significant unmet medical needs within renal therapeutics.

Bull says

  • ↑Complete enrollment of 320 patients in Phase 3 PROACT trial; topline data due Q2 2027
  • ↑$181.6 million cash reserves fund operations through mid-2027, enabling pipeline advancement
  • ↑Market for chronic kidney disease therapies expanding amid rising patient prevalence
  • ↑Positive earnings revision trends indicate growing analyst optimism ahead of trial results
  • ↑Successful Phase 3 efficacy could transform growth trajectory and unlock shareholder value
  • ↑Favorable qualitative factor profile suggests undervaluation and potential sentiment shift

Bear says

  • ↓Q2 2026 revenue $0.15 million, missing estimates by 31.8%, highlighting weak commercial dynamics
  • ↓Q2 2026 loss per share $0.15 exceeds consensus $0.13 loss, marking consecutive disappointments
  • ↓High cash burn with runway into mid-2027 risks dilution or bankruptcy if trial delays occur
  • ↓Past Phase 2 data lacked robust efficacy, increasing probability of negative Phase 3 outcomes
  • ↓Elevated short interest reflects strong market skepticism and potential downward pressure
  • ↓Negative profitability and valuation metrics underscore challenges in generating sustainable returns

Investment themes with PROK

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR